Compare BBSI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | VTYX |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.4M | 990.9M |
| IPO Year | 1993 | 2021 |
| Metric | BBSI | VTYX |
|---|---|---|
| Price | $36.68 | $13.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $45.50 | $13.50 |
| AVG Volume (30 Days) | 139.7K | ★ 6.0M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 10.03 | N/A |
| EPS | ★ 2.08 | N/A |
| Revenue | ★ $1,223,992,000.00 | N/A |
| Revenue This Year | $10.70 | N/A |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | ★ 9.64 | N/A |
| 52 Week Low | $33.01 | $0.78 |
| 52 Week High | $49.65 | $25.00 |
| Indicator | BBSI | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 75.17 |
| Support Level | $37.30 | $13.94 |
| Resistance Level | $37.93 | $14.07 |
| Average True Range (ATR) | 0.86 | 0.05 |
| MACD | -0.23 | -0.07 |
| Stochastic Oscillator | 13.37 | 63.16 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.